



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61P 37/08 (2006.01)
G01N 33/577 (2006.01)

(21) International Application Number:

PCT/SG2022/050336

(22) International Filing Date:

20 May 2022 (20.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202105379W 21 May 2021 (21.05.2021) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: CHOO, Boon Hwa Andre; c/o Bioprocessing Technology Institute (BTI), 20 Biopolis Way, #04-01 Centros, Singapore 138668 (SG). GOH, Ting Hwee; c/o Bioprocessing Technology Institute (BTI), 20 Biopolis Way, #04-01 Centros, Singapore 138668 (SG). DING, Mei Yee; c/o Bioprocessing Technology Institute (BTI), 20 Biopolis Way, #04-01 Centros, Singapore 138668 (SG). LEUNG, Hau Wan; c/o Bioprocessing Technology Institute (BTI), 20 Biopolis Way, #04-01 Centros, Singapore 138668 (SG). DORFMUELLER, Simone; c/o Experimental Drug Development Centre (EDDC), 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG).

TAN, Ban Xiong; c/o Experimental Drug Development Centre (EDDC), 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). LIM, Chek Shik; c/o Experimental Drug Development Centre (EDDC), 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG). STUNKEL, Walter; c/o Experimental Drug Development Centre (EDDC), 10 Biopolis Road, #05-01 Chromos, Singapore 138670 (SG).

(74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTI-CEACAM5/6 ANTIGEN-BINDING MOLECULES AND METHODS OF TREATMENT THEREOF




Figure 13

(57) Abstract: The invention relates to anti-CEACAM5/6 antigen-binding molecules and humanized variants thereof that bind to CEACAM5/6 that is glycosylated at N256. It also relates to the use of said antigen-binding molecules in methods of detection and medical treatment thereof.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

02 February 2023 (02.02.2023)